RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Seres Therapeutics Stock

Seres Therapeutics ROCE 2024

Seres Therapeutics ROCE

2.41

Ticker

MCRB

ISIN

US81750R1023

WKN

A14VXX

In 2024, Seres Therapeutics's return on capital employed (ROCE) was 2.41, a -110.55% increase from the -22.82 ROCE in the previous year.

Seres Therapeutics Aktienanalyse

What does Seres Therapeutics do?

Seres Therapeutics Inc is a company specializing in the development of microbiome therapeutics. The company was founded in 2010 by a group of scientists from Harvard University who recognized the potential of the microbiome and were excited by the fact that it has a multitude of impacts on human health. Seres Therapeutics' headquarters are located in Cambridge, Massachusetts, USA. The business model of Seres Therapeutics is based on the research, development, and commercialization of therapeutics based on the microbiome. The microbiome is the collection of all microorganisms, including bacteria, viruses, and fungi, that live in the human body. Seres Therapeutics firmly believes that the microbiome plays a crucial role in maintaining health and aims to develop innovative therapies that can improve the immune system and strengthen the body's defenses based on this. Seres Therapeutics' products are designed for the treatment of gastrointestinal tract diseases, including inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. The company's products harness the potential of the microbiome to improve gut health, particularly by restoring the natural balance of gut flora. In 2016, Seres Therapeutics launched its first approved drug on the market - SER-109, a treatment for recurrent Clostridium difficile infections (CDI). CDI is an infectious disease caused by the bacterium Clostridium difficile and is commonly associated with antibiotic therapies. SER-109 has proven effective in reducing the frequency of CDI infections, making it the first approved microbiome-based therapeutic. Seres Therapeutics is also working on the development of other products. The company has conducted several Phase 2 clinical trials demonstrating the efficacy of its preparations for the treatment of inflammatory bowel disease. Other products in Seres Therapeutics' pipeline are currently being tested for their effectiveness in combating cancer and autoimmune diseases, where the microbiome also plays an important role. Seres Therapeutics is also working to expand its business into other markets. The company has entered into partnerships with leading pharmaceutical companies such as Nestlé and AstraZeneca to explore the potential of microbiome therapy in various indications. Another important initiative of Seres Therapeutics is the exploration of the use of artificial intelligence to identify new microbiome-based therapeutics and improve drug development. Overall, Seres Therapeutics Inc has written a fascinating story by recognizing the potential of the microbiome in combating diseases. The company is on track to become a leading provider of microbiome-based therapeutics and continues its efforts to provide innovative solutions to future medical challenges. Seres Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Seres Therapeutics's Return on Capital Employed (ROCE)

Seres Therapeutics's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Seres Therapeutics's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Seres Therapeutics's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Seres Therapeutics’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Seres Therapeutics stock

What is the ROCE (Return on Capital Employed) of Seres Therapeutics this year?

The ROCE of Seres Therapeutics is 2.41 undefined this year.

How has the ROCE (Return on Capital Employed) of Seres Therapeutics developed compared to the previous year?

The ROCE of Seres Therapeutics has increased by -110.55% decreased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Seres Therapeutics?

A high Return on Capital Employed (ROCE) indicates that Seres Therapeutics has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Seres Therapeutics?

A low ROCE (Return on Capital Employed) can indicate that Seres Therapeutics has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Seres Therapeutics impact the company?

An increase in the ROCE of Seres Therapeutics can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Seres Therapeutics affect the company?

A decrease in ROCE of Seres Therapeutics can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Seres Therapeutics?

Some factors that can affect Seres Therapeutics's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Seres Therapeutics so important for investors?

The ROCE of Seres Therapeutics is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Seres Therapeutics take to improve the ROCE?

To improve the ROCE, Seres Therapeutics can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Seres Therapeutics pay?

Over the past 12 months, Seres Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Seres Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Seres Therapeutics?

The current dividend yield of Seres Therapeutics is .

When does Seres Therapeutics pay dividends?

Seres Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Seres Therapeutics?

Seres Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Seres Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Seres Therapeutics located?

Seres Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Seres Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Seres Therapeutics from 9/27/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/27/2024.

When did Seres Therapeutics pay the last dividend?

The last dividend was paid out on 9/27/2024.

What was the dividend of Seres Therapeutics in the year 2023?

In the year 2023, Seres Therapeutics distributed 0 USD as dividends.

In which currency does Seres Therapeutics pay out the dividend?

The dividends of Seres Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Seres Therapeutics

Our stock analysis for Seres Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Seres Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.